Health
China Marches into the Era of Interventional Direct Annuloplasty
Launching of the 1st Human Implantation of "DragonRing" – Catheter-based Mitral Annuloplasty Device HANGZHOU, China, Nov. 5, 2022 /PRNewswire/ -- On October 28, 2022, a multidisciplinary, and international cardiac team led by ProfessorMao Chen from Department of Cardiology, West China Hospital,S...
2022-11-06 01:44
2644
Waterdrop Launches Insurance against Breast Cancer Recurrence
BEIJING, Nov. 4, 2022 /PRNewswire/ -- The National Cancer Institute(NCI)'s SEER statistics show that breast cancer recurrence rate is as much as 30%. According to the 2022 White Paper on the Quality of Life of Breast Cancer Patients inChina , more than 70% of breast cancer patients are worried abo...
2022-11-04 22:30
4234
Waterdrop Wins the NBD "Annual Insurtech Progress Award"
BEIJING, Nov. 4, 2022 /PRNewswire/ -- At the recent 2022 Summit on China's Financial Development and the 13th China Jinding (Finance) Awards organized by the National Business Daily(NBD), a nationwide Chinese financial and economic daily newspaper published in Mainland China, Waterdrop won the"An...
2022-11-04 21:30
3907
Certa Therapeutics' investigational drug FT011 delivers breakthrough results as a potential novel treatment for serious inflammatory and fibrotic diseases
* Research presented today by University of Michigan Medical School highlights FT011's ground-breaking treatment potential from human expression profiles in chronic kidney disease study supported by animal model data * The research demonstrated that treatment with FT011 results in a remarkable...
2022-11-04 20:00
2380
Akeso Completes Enrollment in Phase III Trial of PD-1/VEGF Bispecific Antibody (AK112) Combined with Chemotherapy in EGFR-TKI-resistant nsq-NSCLC
HONG KONG, Nov. 3, 2022 /PRNewswire/ -- Akeso, Biopharma (9926. HK) ("Akeso") announced the patient enrollment completion for the Phase III clinical trial of Ivonescimab (PD-1/VEGF bi-specific antibody, AK112) combined with chemotherapy for the treatment of EGFR-mutant locally advanced or metasta...
2022-11-04 08:57
1602
ASH 2022 | Ascentage Pharma to Present Initial Data of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Combination with BTK Inhibitors for the Treatment of R/R CLL/SLL, Including an ORR of 98%, in an Oral Report at the ASH Annual Meeting
SUZHOU, China, and ROCKVILLE, Md., Nov. 3, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the initial results from a global Phase II st...
2022-11-04 03:33
2520
ASH 2022 | Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, at the ASH Annual Meeting
SUZHOU, China, and ROCKVILLE, Md., Nov. 3, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the updated results from three studies of ...
2022-11-04 03:32
1962
Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed Multiple Myeloma at 64th American Society of Hematology Annual Meeting & Exposition
BCMA/CD19 dual-targeting FasTCAR-T GC012F demonstrated 100% ORR and 100% MRD negativity in the 13 patients treated SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, Nov. 3, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharm...
2022-11-03 21:10
2011
I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022
GAITHERSBURG, MD. and SHANGHAI, Nov. 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that two poster presentations featuring preclinical and ...
2022-11-03 21:01
2268
2nd Global Forum of People's Organizations on Hansen's Disease Focuses on Capacity Building to Promote Dignity of Those Affected by the Disease
TOKYO, Nov. 3, 2022 /PRNewswire/ -- The 2nd Global Forum of People's Organizations on Hansen's Disease takes place inHyderabad, India, from November 6 to 8, 2022. Organized by Sasakawa Leprosy (Hansen's Disease) Initiative as part of its "Don't Forget Leprosy" campaign, the forum is being held a...
2022-11-03 21:00
1814
Yuyu Pharma attendance at European Pharmaceutical Conference
SEOUL, South Korea, Nov. 3, 2022 /PRNewswire/ -- Robert Yu, CEO of Yuyu Pharma,
has been attending biopharmaceutical conferences held inGermany, BIO-Europe and
CPHI. The purpose is to explore opportunities to expand into international
markets, such as Europe.
2022-11-03 21:00
2082
Zhongchao Inc.'s China Operating Entity, Chongqing Xinjiang Pharmaceutical Co., Ltd. Obtained Pharmaceutical Trade and Medical Device Operation Licenses, Ready to Enter Into Pharmaceuticals Circulation Market
SHANGHAI, Nov. 3, 2022 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that one of theChina operating entities of which the Company cons...
2022-11-03 19:30
1805
Five New Drug Candidates Show Promise as Ainos Pursues Licensing Partners of its Low-dose Oral Interferon Formulation
The FDA gave positive feedback regarding filing a Biologics License Application (BLA) for Sjögren's syndrome following two Phase 3 studies Ainos is seeking out-licensing opportunities to accelerate the process of bringing five new drug candidates to Phase 3 trials and eventual commercialization ...
2022-11-03 19:00
1539
Eccogene Announces US IND Approval for GLP-1 Receptor Agonist ECC5004
BOSTON and SHANGHAI, Nov. 3, 2022 /PRNewswire/ -- Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence a Phase I trial of its glucagon-like peptide 1 receptor agonist (GLP-1 RA) ECC5004 for type 2 diabetes mell...
2022-11-03 13:11
1933
Shanghai Operation Robot announced the first Robot-assisted human clinical trial of biliary stent placement surgery
SHANGHAI, Nov. 2, 2022 /PRNewswire/ -- Shanghai Operation Robot Co.,Ltd announced the results of its initial clinical trial of ERCP (Endoscopic retrograde cholangiopancreatography) robot in biliary stent placement surgery. It is the first Robot-assisted human clinical trial of biliary stent place...
2022-11-02 13:55
1642
WAT Medical Entrusted By Geely Auto To Develop Neuromodulation Technologies To Improve Travel Experiences
VANCOUVER, BC, Nov. 1, 2022 /PRNewswire/ -- With the foreseeable increase in outdoor travelling in the near future, as well as the ever-expanding prospects of self-driving vehicles that have been reported to increase the incidence of nausea and vomiting, motion sickness is becoming a continuously...
2022-11-02 01:15
2174
I Peace partners with the California Institute for Regenerative Medicine [CIRM]
PALO ALTO, Calif., Nov. 1, 2022 /PRNewswire/ -- I Peace, Inc. (
https://www.ipeace.com
2022-11-02 00:00
2190
Real-World Application of Lunit INSIGHT to be Spotlighted at RSNA 2022 (Oral Presentations)
* 7 oral presentations and 1 e-poster highlighting Lunit's most up-to-date research on its AI solution for radiology, have been accepted by RSNA * Program will include studies evaluating the performance of Lunit's commercial AI software across massive real-world population groups * Software ...
2022-11-01 22:00
2317
Eyeguard System, the Privacy Filter Specialist, Launched New Wellness & Lifestyle Brand "ANBAC"
Healthy Eyes, Mind, and Body
SEOUL, South Korea, Nov. 1, 2022 /PRNewswire/ -- Eyeguard System, a privacy
filter manufacturer with 20 years of experience, announced that it will launch
"ANBAC", new wellness & lifestyle brand for improving life starting from
relived eyes.
2022-11-01 21:00
1709
New Randomized Controlled Study Published in JAMA Demonstrates the Value of Clinical Decision Support Tools in Preventing Acute Kidney Injury in Patients Undergoing Coronary Angiography
– Researchers used Terumo Health Outcomes' ePRISM® software to calculate safe
contrast volume targets and improve overall patient outcomes –
SOMERSET, N.J., Nov. 1, 2022 /PRNewswire/ -- A new study published in JAMA
2022-11-01 20:00
1451
Week's Top Stories
Most Reposted
Brankas Launches Integrated APAC Open Banking Compliance Solution with ADVANCE.AI's eKYC Solution
[Picked up by 319 media titles]
2024-11-07 09:00
Going Global: DCITS Embarks on International Expansion at Singapore Fintech Festival
[Picked up by 311 media titles]
2024-11-12 09:00
Ubiqconn Technology to Showcase Latest Marine Solutions at the 2024 International WorkBoat Show in New Orleans
[Picked up by 289 media titles]
2024-11-11 21:00
DKSH Healthcare and Euris Unveil CRM & MCE Platform "ConnectPlus" to Revolutionize APAC Healthcare Distribution
[Picked up by 288 media titles]
2024-11-13 09:00
Sobot Introduces its All-in-One Solution at GITEX Global 2024
[Picked up by 285 media titles]
2024-11-12 11:00
Most Read
Mastercard goes OTP-free in APAC for faster, safer online transactions
2024-11-06 09:00
13462
Brankas Launches Integrated APAC Open Banking Compliance Solution with ADVANCE.AI's eKYC Solution
2024-11-07 09:00
10126
XtalPi and Sinar Mas Multiartha Launch Strategic Partnership to Revolutionize AI Across Asia-Pacific
2024-11-07 11:34
7487
XTEP's First Mono Store in Malaysia Comes to Puchong
2024-11-07 10:08
6205
